NEXT GEN - PHILIPS OPTIMUS

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-50
SponsorPhilips Clinical & Medical Affairs Global

About this trial

The purpose of this clinical study is to validate the SpO2 accuracy performance of the sponsor's SpO2 sensors over the range of 70-100% SaO2 during non-motion conditions assessed by CO-Oximetry.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Participant must have the ability to understand and provide written informed consent.

Participant is an adult between 18-50 years of age.

Participant must be willing and able to comply with study procedures and duration.

Participant is a non-smoker or who has not smoked within 2 days prior to the study.

Disqualifiers

Participant is considered as being morbidly obese (defined as BMI >39.5)

Compromised circulation (i.e., Raynaud's Syndrome), injury, open wound, or physical malformation of fingers, toes, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. Tattoos in the optical path which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the sites utilized.)

Females who are pregnant

Females who are trying to get pregnant (with confirmation of positive urine pregnancy test unless the participant is known to be not of child-bearing potential)

Trial population

At least 36 participants considered healthy, non-smoking (or have refrained from smoking for 2 days) competent adults, ages 18 to 50 years.

Trial design

Design model

Other

Time perspective

Prospective

Treatments tested in this trial

  • Philips MR400 Pro MRI Patient Monitor

    Device

    Philips IntelliVue Patient Monitor X3 Philips Adult SpO2 Sensor (M1191BL) Philips Wireless Patient Module SpO2 (Gen-4) SpO2 Sensor, MRI (Gen-4) Adult SpO2 Glove Adult SpO2 Grips

Treatment groups

36 Participants
are divided into 1 treatment group
Group A: Study Population - 18 to 50 Years1 intervention

Trial outcomes

Primary outcomes

1

SpO2 accuracy

SpO2 accuracy will be evaluated for root-mean-square (rms) difference between the DUT and the reference for the specified SpO2 ranges (70-100%) and by SaO2 decade (90-100%, 80\<90%, 70-\<80%).

Time frame
March-April 2026

Secondary outcomes

1

Assess Pigmentation

To assess pigmentation differential bias of the SpO2 sensors under non-motion conditions using the Philips MRI Patient Monitoring Pulse Oximetry Subsystem, in accordance with Philips and ISO methods.

Time frame
March-April 2026

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.